Loading...

Jonathan S Lopresti, MD

Title(s)Associate Professor of Clinical Medicine
Phone+1 323 226 4632
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    Department of Medicine, USC1997Attending of the Year for Internal Medicine
    Keck School of Medicine of USC1998Professor of the Year for Fourth Year Students
    Keck School of Medicine of USC2015Faculty Teaching Award, Year II
    Keck School of Medicine of USC2015Faculty Teaching Award, Year IV

    Collapse Overview 
    Collapse Overview
    A native of Los Angeles, Dr. LoPresti received both his medical degree and his Ph.D. in physiology from the University of Southern California. He first joined the Trojan family in 1974 as a biology undergraduate and finished his residency at the LAC+USC Medical Center ten years later. Dr. LoPresti has contributed to over fifty presentations, recently lecturing on a case of an aggressive Papillary Thyroid Cancer arising in the third trimester of pregnancy. In addition, he has had leadership roles in the American Thyroid Association and has been published in numerous journals, abstracts and book chapters.

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Schmidt RL, LoPresti JS, McDermott MT, Zick SM, Straseski JA. Does Reverse Triiodothyronine Testing Have Clinical Utility? An Analysis of Practice Variation Based on Order Data from a National Reference Laboratory. Thyroid. 2018 07; 28(7):842-848. PMID: 29756541.
      View in: PubMed
    2. Spencer C, Petrovic I, Fatemi S, LoPresti J. Serum thyroglobulin (Tg) monitoring of patients with differentiated thyroid cancer using sensitive (second-generation) immunometric assays can be disrupted by false-negative and false-positive serum thyroglobulin autoantibody misclassifications. J Clin Endocrinol Metab. 2014 Dec; 99(12):4589-99. PMID: 25226290.
      View in: PubMed
    3. Angell TE, Lechner MG, Nguyen CT, Salvato VL, Nicoloff JT, LoPresti JS. Clinical features and hospital outcomes in thyroid storm: a retrospective cohort study. J Clin Endocrinol Metab. 2015 Feb; 100(2):451-9. PMID: 25343237.
      View in: PubMed
    4. Angell TE, Lechner MG, Jang JK, LoPresti JS, Epstein AL. MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro. Clin Cancer Res. 2014 Dec 01; 20(23):6034-44. PMID: 25294906.
      View in: PubMed
    5. Spencer C, LoPresti J, Fatemi S. How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies. Curr Opin Endocrinol Diabetes Obes. 2014 Oct; 21(5):394-404. PMID: 25122493.
      View in: PubMed
    6. Kaptein EM, LoPresti JS, Kaptein MJ. Is an isolated TSH elevation in chronic nonthyroidal illness "subclinical hypothyroidism"? J Clin Endocrinol Metab. 2014 Nov; 99(11):4015-26. PMID: 25166720.
      View in: PubMed
    7. Angell TE, Lechner MG, Jang JK, Correa AJ, LoPresti JS, Epstein AL. BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration. Thyroid. 2014 Sep; 24(9):1385-93. PMID: 24955518.
      View in: PubMed
    8. Angell TE, Spencer CA, Rubino BD, Nicoloff JT, LoPresti JS. In search of an unstimulated thyroglobulin baseline value in low-risk papillary thyroid carcinoma patients not receiving radioactive iodine ablation. Thyroid. 2014 Jul; 24(7):1127-33. PMID: 24697314.
      View in: PubMed
    9. Spencer C, Fatemi S, Singer P, Nicoloff J, Lopresti J. Serum Basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer. Thyroid. 2010 Jun; 20(6):587-95. PMID: 20470203.
      View in: PubMed
    10. Spencer CA, Lopresti JS. Measuring thyroglobulin and thyroglobulin autoantibody in patients with differentiated thyroid cancer. Nat Clin Pract Endocrinol Metab. 2008 Apr; 4(4):223-33. PMID: 18268520.
      View in: PubMed
    11. Spencer CA, Bergoglio LM, Kazarosyan M, Fatemi S, LoPresti JS. Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2005 Oct; 90(10):5566-75. PMID: 15985472.
      View in: PubMed
    12. Fatemi S, LoPresti JS. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003 Sep; 88(9):4507-8; author reply 4508-10. PMID: 12970333.
      View in: PubMed
    13. Greaves TS, Olvera M, Florentine BD, Raza AS, Cobb CJ, Tsao-Wei DD, Groshen S, Singer P, Lopresti J, Martin SE. Follicular lesions of thyroid: a 5-year fine-needle aspiration experience. Cancer. 2000 Dec 25; 90(6):335-41. PMID: 11156516.
      View in: PubMed
    14. Spencer CA, LoPresti JS, Fatemi S, Nicoloff JT. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Thyroid. 1999 May; 9(5):435-41. PMID: 10365673.
      View in: PubMed
    15. Spencer CA, Takeuchi M, Kazarosyan M, Wang CC, Guttler RB, Singer PA, Fatemi S, LoPresti JS, Nicoloff JT. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1998 Apr; 83(4):1121-7. PMID: 9543128.
      View in: PubMed
    16. LoPresti JS. Laboratory tests for thyroid disorders. Otolaryngol Clin North Am. 1996 Aug; 29(4):557-75. PMID: 8844730.
      View in: PubMed
    17. Spencer CA, LoPresti JS, Nicoloff JT, Dlott R, Schwarzbein D. Multiphasic thyrotropin responses to thyroid hormone administration in man. J Clin Endocrinol Metab. 1995 Mar; 80(3):854-9. PMID: 7883842.
      View in: PubMed
    18. LoPresti JS, Nicoloff JT. 3,5,3'-Triiodothyronine (T3) sulfate: a major metabolite in T3 metabolism in man. J Clin Endocrinol Metab. 1994 Mar; 78(3):688-92. PMID: 8126143.
      View in: PubMed
    19. Nicoloff JT, LoPresti JS. Myxedema coma. A form of decompensated hypothyroidism. Endocrinol Metab Clin North Am. 1993 Jun; 22(2):279-90. PMID: 8325287.
      View in: PubMed
    20. Spencer CA, Schwarzbein D, Guttler RB, LoPresti JS, Nicoloff JT. Thyrotropin (TSH)-releasing hormone stimulation test responses employing third and fourth generation TSH assays. J Clin Endocrinol Metab. 1993 Feb; 76(2):494-8. PMID: 8432796.
      View in: PubMed
    21. Mehra A, Widerhorn J, Lopresti J, Rahimtoola SH. Amiodarone-induced hyperthyroidism: thyroidectomy under local anesthesia. Am Heart J. 1991 Oct; 122(4 Pt 1):1160-1. PMID: 1927868.
      View in: PubMed
    22. LoPresti JS, Mizuno L, Nimalysuria A, Anderson KP, Spencer CA, Nicoloff JT. Characteristics of 3,5,3'-triiodothyronine sulfate metabolism in euthyroid man. J Clin Endocrinol Metab. 1991 Oct; 73(4):703-9. PMID: 1890147.
      View in: PubMed
    23. LoPresti JS, Gray D, Nicoloff JT. Influence of fasting and refeeding on 3,3',5'-triiodothyronine metabolism in man. J Clin Endocrinol Metab. 1991 Jan; 72(1):130-6. PMID: 1986011.
      View in: PubMed
    24. LoPresti JS, Anderson KP, Nicoloff JT. Does a hidden pool of reverse triiodothyronine (rT3) production contribute to total thyroxine (T4) disposal in high T4 states in man. J Clin Endocrinol Metab. 1990 May; 70(5):1479-84. PMID: 2335581.
      View in: PubMed
    25. Fried JC, LoPresti JS, Micon M, Bauer M, Tuchschmidt JA, Nicoloff JT. Serum triiodothyronine values. Prognostic indicators of acute mortality due to Pneumocystis carinii pneumonia associated with the acquired immunodeficiency syndrome. Arch Intern Med. 1990 Feb; 150(2):406-9. PMID: 2302016.
      View in: PubMed
    26. Spencer CA, LoPresti JS, Patel A, Guttler RB, Eigen A, Shen D, Gray D, Nicoloff JT. Applications of a new chemiluminometric thyrotropin assay to subnormal measurement. J Clin Endocrinol Metab. 1990 Feb; 70(2):453-60. PMID: 2105333.
      View in: PubMed
    27. LoPresti JS, Eigen A, Kaptein E, Anderson KP, Spencer CA, Nicoloff JT. Alterations in 3,3'5'-triiodothyronine metabolism in response to propylthiouracil, dexamethasone, and thyroxine administration in man. J Clin Invest. 1989 Nov; 84(5):1650-6. PMID: 2808705.
      View in: PubMed
    28. LoPresti JS, Fried JC, Spencer CA, Nicoloff JT. Unique alterations of thyroid hormone indices in the acquired immunodeficiency syndrome (AIDS) Ann Intern Med. 1989 Jun 15; 110(12):970-5. PMID: 2567143.
      View in: PubMed
    29. Gray DS, Takahashi M, Fisler JS, LoPresti J, Nicoloff JT, Bray GA. Effect of carbohydrate refeeding on free fatty acids after a fast in obese diabetic and obese non-diabetic females. Metabolism. 1989 Mar; 38(3):208-14. PMID: 2645502.
      View in: PubMed
    30. Spencer CA, Lai-Rosenfeld AO, Guttler RB, LoPresti J, Marcus AO, Nimalasuriya A, Eigen A, Doss RC, Green BJ, Nicoloff JT. Thyrotropin secretion in thyrotoxic and thyroxine-treated patients: assessment by a sensitive immunoenzymometric assay. J Clin Endocrinol Metab. 1986 Aug; 63(2):349-55. PMID: 3088021.
      View in: PubMed
    31. LoPresti JS, Warren DW, Kaptein EM, Croxson MS, Nicoloff JT. Urinary immunoprecipitation method for estimation of thyroxine to triiodothyronine conversion in altered thyroid states. J Clin Endocrinol Metab. 1982 Oct; 55(4):666-70. PMID: 7050140.
      View in: PubMed
    32. Warren DW, LoPresti JS, Nicoloff JT. A new method for measurement of the conversion ratio of thyroxine to triiodothyronine in euthyroid man. J Clin Endocrinol Metab. 1981 Dec; 53(6):1218-22. PMID: 7298801.
      View in: PubMed